No benefit from adjuvant sunitinib, sorafenib in locally advanced renal cell carcinoma
the ONA take:
According to initial results presented this week at the 2015 Genitourinary Cancers Symposium in Orlando, Florida, the use of either Nexavar (sorafenib) or Sutent (sunitinib) provide no benefit to patients with locally advanced renal cell carcinoma who are at a high risk of recurrence.
The phase 3 trial conducted by the ECOG-ACRIN Cancer Research Group is the first and largest study reporting on the efficacy of sunitinib or sorafenib in patients who have undergone surgery to remove the kidney tumor.
"Unfortunately we found that the use of sunitinib or sorafenib in this setting did not reduce the incidence of recurrence as compared to standard care," said lead researcher Naomi B. Haas, MD, from the University of Pennsylvania's Abramson Cancer Center in Philadelphia.
For the international, phase III study, researchers enrolled 1,943 patients considered at high risk for recurrence following surgery to remove a kidney tumor and randomly assigned them to receive sorafenib, sunitinib, or placebo for 1 year.
Results of the study showed a median progression-free survival of 5.6 years for those treated with sunitinib compared with 5.6 years for those treated with sorafenib and 5.7 years for those who received placebo.
Use of either Nexavar (sorafenib) or Sutent (sunitinib) provide no benefit to patients with locally advanced renal cell carcinoma.
- More Than Half of Melanomas Are Self-Detected, Especially by Women
- Childhood Cancer Linked to Poor Diet Quality in Adult Survivors
- New Research Identifies Potential Bladder Cancer Chemotherapy Side Effect
- Olaratumab in Combo With Doxorubicin Approved for Soft Tissue Sarcoma
- Hydroxyurea May Improve Kidney Function in PV-Associated Nephrotic Syndrome
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication
- Study Identifies Factors Associated With Infection-related Complications in ALL
- Immune Checkpoint-Related Neurotoxicity May Be More Common During Combination Treatment
- New Recommendations for Secondary Prevention of Cervical Cancer
- Nonadherence to Posttreatment Imaging Follow-up Common Among Breast Cancer Survivors
- HIIT Improves Cardiorespiratory Fitness in Patients With Resectable NSCLC
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|